Prognosis for Metastatic Prostate Cancer

Prognostic Factors

The median overall survival for patients with metastatic prostate cancer ranges from 18-36 months, with significant variations based on disease volume, PSA doubling time, and response to treatment 1, 2
High-volume disease is associated with worse outcomes compared to low-volume disease 1
Presence of symptoms, particularly bone pain, at initial presentation is associated with poorer 10-year survival 1
Rapid PSA doubling time indicates more aggressive disease and higher risk of developing metastatic progression 3, 2
Patients with visceral metastases generally have more aggressive disease and poorer prognosis than those with bone-only metastases 4
Patients who develop castration resistance quickly after initial androgen deprivation therapy have worse outcomes 2

The STAMPEDE trial demonstrated that only men with low-volume metastatic disease showed survival improvement with radiotherapy in combination with ADT 1

Median survival is less than 2 years for patients with castration-resistant disease and bone metastases 4
Patients with visceral metastases generally have worse outcomes, with median survival typically 30-50% shorter than those with bone-only disease 4

Germline mutations in DNA repair genes are associated with worse prognosis, with cancer-specific survival approximately half that of men without such mutations 2
Approximately 11.8% of men with metastatic prostate cancer have inherited DNA repair mutations, which may affect treatment response and prognosis 1

Regular monitoring with PSA testing every 3-6 months after initiation of ADT is recommended 1
Periodic conventional imaging should be considered, with frequency determined by treatment response and symptoms 1
PSA progression alone does not always correlate with radiographic progression 2
Bone metastases may paradoxically appear worse on imaging despite effective treatment, potentially leading to false interpretation of disease progression 4

Genetic testing is increasingly important for identifying patients who may benefit from targeted therapies such as PARP inhibitors, potentially improving survival in specific subgroups 2